CN116368140A - 杂环glp-1激动剂 - Google Patents

杂环glp-1激动剂 Download PDF

Info

Publication number
CN116368140A
CN116368140A CN202180073093.9A CN202180073093A CN116368140A CN 116368140 A CN116368140 A CN 116368140A CN 202180073093 A CN202180073093 A CN 202180073093A CN 116368140 A CN116368140 A CN 116368140A
Authority
CN
China
Prior art keywords
alkyl
independently selected
compound
optionally substituted
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180073093.9A
Other languages
English (en)
Chinese (zh)
Inventor
孟庆华
邢唯强
张海珍
林熹晨
雷晖
A·詹宁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gashubrum Biology
Original Assignee
Gashubrum Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gashubrum Biology filed Critical Gashubrum Biology
Publication of CN116368140A publication Critical patent/CN116368140A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180073093.9A 2020-09-10 2021-09-08 杂环glp-1激动剂 Pending CN116368140A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020114319 2020-09-10
CNPCT/CN2020/114319 2020-09-10
PCT/CN2021/117263 WO2022052958A1 (en) 2020-09-10 2021-09-08 Heterocyclic glp-1 agonists

Publications (1)

Publication Number Publication Date
CN116368140A true CN116368140A (zh) 2023-06-30

Family

ID=80632099

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180073093.9A Pending CN116368140A (zh) 2020-09-10 2021-09-08 杂环glp-1激动剂

Country Status (5)

Country Link
US (1) US12595264B2 (https=)
EP (1) EP4211139A4 (https=)
JP (1) JP2023540609A (https=)
CN (1) CN116368140A (https=)
WO (1) WO2022052958A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119176808A (zh) * 2024-11-25 2024-12-24 山东法恩新材料科技有限公司 一种glp-1激动剂及其制备方法和应用
WO2025026270A1 (zh) * 2023-07-28 2025-02-06 上海翰森生物医药科技有限公司 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用
WO2025103443A1 (zh) * 2023-11-16 2025-05-22 海思科医药集团股份有限公司 一种咪唑-2-酮衍生物及其在医药上的应用
WO2025108361A1 (zh) * 2023-11-21 2025-05-30 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
WO2025119206A1 (en) * 2023-12-05 2025-06-12 Fortvita Biologics Inc. Glp-1 receptor targeting compounds and uses thereof
WO2025176130A1 (zh) * 2024-02-19 2025-08-28 上海壹迪生物技术有限公司 一种含吡唑并环类化合物、其药物组合物及其用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023029380A1 (zh) 2021-08-30 2023-03-09 杭州德睿智药科技有限公司 作为glp1r激动剂的新型芳醚取代杂环类化合物
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
IL325536A (en) * 2023-06-30 2026-02-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A compound containing a multi-fused ring structure
WO2025045208A1 (en) * 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
CN121941685A (zh) 2023-11-10 2026-04-28 重庆药友制药有限责任公司 一种glp-1r激动剂化合物及其应用
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2025264023A1 (en) * 2024-06-19 2025-12-26 Chong Kun Dang Pharmaceutical Corp. Glp-1 receptor agonist, and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625847A1 (en) * 2001-07-06 2006-02-15 Merck & Co., Inc. Pharmaceutical composition comprising a tetrahydrotriazolo[4,3-a]pyrazine
CN109790161A (zh) * 2016-09-26 2019-05-21 中外制药株式会社 具有glp-1受体激动剂作用的吡唑并吡啶衍生物
JP2019099571A (ja) * 2017-11-29 2019-06-24 中外製薬株式会社 Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
WO2019166951A1 (en) * 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
US20200017505A1 (en) * 2018-02-01 2020-01-16 Japan Tobacco Inc. Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof
WO2020089455A1 (en) * 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020089453A1 (en) * 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
CN116390926A (zh) * 2020-07-20 2023-07-04 上海诚益生物科技有限公司 四氢吡唑并-吡嗪基-二氢咪唑酮或四氢吡唑并-吡啶基-二氢咪唑酮化合物及其使用方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212435B (en) 1990-06-07 1996-06-28 Sandoz Ag Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients.
WO1995001961A1 (en) 1993-07-09 1995-01-19 Schering Corporation Process for the synthesis of azetidinones
JPH08295646A (ja) 1995-04-26 1996-11-12 Teijin Ltd ビス（ヒドロキシエトキシフェニル）化合物の製造方法
US6187774B1 (en) 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
AU5907898A (en) 1997-01-13 1998-08-03 Penn State Research Foundation, The Asymmetric synthesis and catalysis with chiral heterocyclic compounds
IT1292461B1 (it) 1997-07-03 1999-02-08 Great Lakes Chemical Italia Composti fotocromatici,procedimento per la loro preparazione e loro utilizzo in materiali polimerici
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
EP1237547A2 (en) 1999-07-09 2002-09-11 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
WO2002046164A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic compounds
BR0116468A (pt) 2000-12-08 2004-06-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituìda por indazolila como inibidores de cinase
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
US7192939B2 (en) 2002-01-30 2007-03-20 Montana State University Pestalotiopsis microsporia isolates and compounds derived therefrom
KR20050043967A (ko) 2002-09-17 2005-05-11 액테리온 파마슈티칼 리미티드 1-피리딘-4-일-요소 유도체
US20040259179A1 (en) 2003-05-30 2004-12-23 Gerd Assmann Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
ES2319539T3 (es) 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv Compuestos heterociclicos condensados como moduladores del receptor de serotonina.
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005066136A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Bicyclic derivatives as ppar modulators
WO2005112932A2 (en) 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
WO2005121138A2 (en) 2004-06-03 2005-12-22 Rigel Pharmaceuticals, Inc. Heterotricyclic compounds for use as hcv inhibitors
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
WO2006034419A2 (en) 2004-09-21 2006-03-30 Athersys, Inc. Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
EP2298295B1 (en) 2005-01-31 2013-08-28 Cephalon, Inc. Tumor necrosis factor inhibitors
US20090305964A1 (en) 2005-04-21 2009-12-10 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
WO2007009883A1 (en) 2005-07-15 2007-01-25 F. Hoffmann-La Roche Ag Novel heteroaryl fused cyclic amines
SI1931660T1 (sl) 2005-09-29 2012-12-31 Sanofi Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila
JP4955009B2 (ja) 2005-11-11 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー 凝固因子Ｘａの阻害剤としての炭素環式縮合環アミン
EP1986643A1 (en) 2006-02-10 2008-11-05 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP2046333A4 (en) 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
EP2091921A2 (en) 2006-11-03 2009-08-26 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
US20130012485A1 (en) 2006-12-22 2013-01-10 Baeschlin Daniel Kaspar Organic compounds
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
CA2684633A1 (en) 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009036275A1 (en) 2007-09-13 2009-03-19 Link Medicine Corporation Treatment of neurodegenerative diseases using indatraline analogs
WO2009099736A2 (en) 2008-02-06 2009-08-13 Lead Therapeutics, Inc. Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8735391B2 (en) 2008-09-26 2014-05-27 University Of Kansas Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
AR075051A1 (es) 2009-02-05 2011-03-02 Schering Corp Compuestos antidiabeticos que contienen ftalazina
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
JP2013530963A (ja) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド 新規のｇｌｐ−１受容体安定化薬および調節薬
WO2012065065A1 (en) 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
EP2640373A4 (en) 2010-11-16 2014-04-23 Univ New Jersey Med TREATMENT OF TYPE II DIABETES AND DIABETES ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIENE COPPERS
JP5805982B2 (ja) 2011-04-20 2015-11-10 ユニチカ株式会社 ポリアリレート樹脂フィルムおよび気体分離膜
JP5687120B2 (ja) 2011-04-20 2015-03-18 ユニチカ株式会社 ポリアリレート樹脂
KR101401705B1 (ko) 2012-01-31 2014-06-27 울산대학교 산학협력단 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
US20150272939A1 (en) 2012-10-02 2015-10-01 Yale University Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
JP6314335B2 (ja) 2013-02-06 2018-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
NZ708593A (en) 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative
PL3022210T3 (pl) 2013-07-17 2018-08-31 Boehringer Ingelheim International Gmbh Nowy pochodne azabenzimidazolu
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
EP2857550A1 (en) 2013-10-02 2015-04-08 Basf Se Amine precursors for depositing graphene
AR098215A1 (es) 2013-10-29 2016-05-18 Takeda Pharmaceuticals Co Compuesto heterocíclico
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
EP2993174A1 (en) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
CN105646459A (zh) 2014-11-13 2016-06-08 上海和辉光电有限公司 一种化合物及其制备方法和应用
WO2016118639A1 (en) 2015-01-20 2016-07-28 The Trustees Of Columbia University In The City Of New York Small molecule oxidizers of pdi and their use
WO2017182983A1 (en) 2016-04-22 2017-10-26 Sabic Global Technologies B.V. Methods of manufacture of 2-aryl-3,3-bis(hydroxyaryl)phthalimidines
WO2017182986A1 (en) 2016-04-22 2017-10-26 Sabic Global Technologies B.V. Methods of manufacture of 2-aryl-3,3-bis(hydroxyaryl)phthalimidines
WO2017182984A1 (en) 2016-04-22 2017-10-26 Sabic Global Technologies B.V. Methods of manufacture of 2-aryl-3,3-bis (4-hydroxyaryl) phthalimidines, and polymers derived therefrom
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
KR102314286B1 (ko) 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
EP3600270B1 (en) 2017-03-31 2023-06-14 Aurigene Oncology Limited Compounds and compositions for treating hematological disorders
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
JP7264906B2 (ja) 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
WO2019126424A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
MX2020008265A (es) 2018-02-16 2020-09-21 UCB Biopharma SRL Derivados farmaceuticos del anillo heterobiciclico 6,5.
US20190284341A1 (en) 2018-03-14 2019-09-19 Sabic Global Technologies B.V. 3-oxo-2-alkylisoindoline diphthalonitrile monomers, methods of manufacture, thermosetting compositions comprising the same, and uses thereof
US20190284340A1 (en) 2018-03-14 2019-09-19 SABIC Global Technologies B.V 3-oxo-2-arylisoindoline diphthalonitrile monomers, methods of manufacture, thermosetting compositions comprising the same, and uses thereof
BR112020019822A2 (pt) 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
DK3806855T5 (da) 2018-06-15 2023-05-22 Pfizer GLP-1-receptoragonister og anvendelser deraf
WO2020001321A1 (en) 2018-06-27 2020-01-02 The Hong Kong Polytechnic University Compounds with antimicrobial activity
US11923622B2 (en) 2018-08-02 2024-03-05 Nokia Solutions And Networks Oy Antenna and wireless communication device
MA54555A (fr) 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
CN111217796B (zh) 2018-11-26 2021-12-14 上海亚舸生物科技有限公司 一类螺环-二吡咯甲烷/二吡咯甲川化合物及其制备方法和应用
CN111217842B (zh) 2018-11-26 2023-01-31 上海亚舸生物科技有限公司 一类螺环-二吡咯甲烷硼配合物/二吡咯甲川硼配合物及其制备方法和应用
US20220204473A1 (en) 2018-12-25 2022-06-30 Shanghai Meiyue Biotech Development Co., Ltd. Compound as irak inhibitor
WO2020163236A1 (en) 2019-02-04 2020-08-13 The General Hospital Corporation Treating long qt syndrome
CA3132531A1 (en) 2019-03-14 2020-09-17 Janssen Sciences Ireland Unlimited Company Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
EP3953344A4 (en) 2019-04-12 2023-08-09 Qilu Regor Therapeutics Inc. GLP-IR AGONISTS AND THEIR USES
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
CN110804059B (zh) 2019-09-30 2024-03-12 郑州泰基鸿诺医药股份有限公司 氨基甲酸酯类化合物、药物组合物及其应用
EP4048664A1 (en) 2019-10-25 2022-08-31 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2021096284A1 (ko) 2019-11-15 2021-05-20 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
JP7836762B2 (ja) 2020-02-13 2026-03-27 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
EP4211133A4 (en) 2020-09-07 2024-11-27 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
TW202227435A (zh) 2020-09-11 2022-07-16 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之稠合環嘧啶酮衍生物
WO2023016546A1 (en) 2021-08-12 2023-02-16 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2025509281A (ja) 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
TW202435857A (zh) 2022-12-15 2024-09-16 美商迦舒布魯姆生物有限公司 具有glp-1促效劑活性之化合物之鹽及固體形式
CN120659776A (zh) 2022-12-19 2025-09-16 伊莱利利公司 Glp1 ra及其中间体的制备方法
EP4652167A1 (en) 2023-01-17 2025-11-26 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
CN120957993A (zh) * 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2025002250A1 (zh) 2023-06-29 2025-01-02 韦恩生物科技有限公司 一种glp-1受体激动剂及其制备方法和用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625847A1 (en) * 2001-07-06 2006-02-15 Merck & Co., Inc. Pharmaceutical composition comprising a tetrahydrotriazolo[4,3-a]pyrazine
CN109790161A (zh) * 2016-09-26 2019-05-21 中外制药株式会社 具有glp-1受体激动剂作用的吡唑并吡啶衍生物
JP2019099571A (ja) * 2017-11-29 2019-06-24 中外製薬株式会社 Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
US20200017505A1 (en) * 2018-02-01 2020-01-16 Japan Tobacco Inc. Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof
WO2019166951A1 (en) * 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
WO2020089455A1 (en) * 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020089453A1 (en) * 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
CN116390926A (zh) * 2020-07-20 2023-07-04 上海诚益生物科技有限公司 四氢吡唑并-吡嗪基-二氢咪唑酮或四氢吡唑并-吡啶基-二氢咪唑酮化合物及其使用方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025026270A1 (zh) * 2023-07-28 2025-02-06 上海翰森生物医药科技有限公司 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用
WO2025103443A1 (zh) * 2023-11-16 2025-05-22 海思科医药集团股份有限公司 一种咪唑-2-酮衍生物及其在医药上的应用
WO2025108361A1 (zh) * 2023-11-21 2025-05-30 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
WO2025119206A1 (en) * 2023-12-05 2025-06-12 Fortvita Biologics Inc. Glp-1 receptor targeting compounds and uses thereof
WO2025176130A1 (zh) * 2024-02-19 2025-08-28 上海壹迪生物技术有限公司 一种含吡唑并环类化合物、其药物组合物及其用途
CN119176808A (zh) * 2024-11-25 2024-12-24 山东法恩新材料科技有限公司 一种glp-1激动剂及其制备方法和应用

Also Published As

Publication number Publication date
EP4211139A4 (en) 2024-12-18
EP4211139A1 (en) 2023-07-19
US20230331732A1 (en) 2023-10-19
US12595264B2 (en) 2026-04-07
WO2022052958A1 (en) 2022-03-17
JP2023540609A (ja) 2023-09-25

Similar Documents

Publication Publication Date Title
US12595264B2 (en) Heterocyclic GLP-1 agonists
JP7821785B2 (ja) ヘテロ環ｇｌｐ－１アゴニスト
US11897851B2 (en) Heterocyclic GLP-1 agonists
US11926626B2 (en) Heterocyclic GLP-1 agonists
EP4229049A1 (en) Heterocyclic glp-1 agonists
EP4490155A1 (en) Heterocyclic glp-1 agonists
EP4476213A1 (en) Heterocyclic glp-1 agonists
CN119343343A (zh) 杂环glp-1激动剂
WO2023198140A1 (en) Heterocyclic glp-1 agonists
TW202506102A (zh) 雜環的glp-1促效劑
HK40098769A (zh) 杂环glp-1激动剂
HK40119249A (zh) 杂环glp-1激动剂
HK40122544A (zh) 杂环glp-1激动剂
KR20260064683A (ko) 헤테로시클릭 glp-1 효능제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination